REGISTER
Plozasiran Phase III Data Reshape the Severe Hypertriglyceridemia Landscape
Plozasiran’s Phase III SHASTA-3 and SHASTA-4 trials (~750 patients with severe hypertriglyceridemia) showed median triglyceride reductions of 79% and 81% at month 12 versus ~27% with placebo, plus significant reductions in acute pancreatitis events including 100% reduction in the highest-risk subgroup. This article reviews the competitive landscape with Ionis’s olezarsen (Tryngolza), the first FDA-approved sHTG therapy, and the expanding market and ongoing patent disputes.

On July 22, Arrowhead Pharmaceuticals announced that its siRNA therapy plozasiran had achieved comprehensive positive topline results in two global Phase III clinical trials — SHASTA-3 and SHASTA-4 — for severe hypertriglyceridemia (sHTG). The news triggered a strong market reaction, with Arrowhead’s stock rising to its highest level in more than five years and gaining more than 20% intraday.

Just one month earlier, on June 24, 2026, Ionis’s olezarsen received FDA approval as an adjunct to diet for reducing triglyceride levels and the risk of acute pancreatitis in adults with sHTG.

With the Phase III readout for plozasiran, the head-to-head competition between the two APOC3-targeted nucleic acid therapies in the sHTG space has officially begun.

The Heavy Burden of sHTG and Acute Pancreatitis

Severe hypertriglyceridemia (sHTG) is a pathological state of abnormally elevated blood triglyceride (TG) levels, clinically defined as TG above 500 mg/dL. When TG levels become extremely elevated, blood viscosity increases, damaging vascular endothelium, accelerating atherosclerosis, and severely disrupting the microcirculation — with particularly toxic effects on pancreatic tissue.

Acute pancreatitis (AP) is one of the most dangerous complications of sHTG. It is an acute, severe inflammation of the pancreas, typically presenting with intense abdominal pain, nausea, and vomiting; severe cases often require prolonged hospitalization and may progress to multi-organ failure and death. The risk of AP rises sharply with TG levels, increasing exponentially once TG exceeds 880 mg/dL. Familial chylomicronemia syndrome (FCS), the most severe subtype of sHTG, is characterized by extremely high TG levels (often >880 mg/dL) and recurrent episodes of acute pancreatitis, along with chronic abdominal pain, diabetes, hepatic steatosis, and cognitive impairment.

This large patient population has long faced a scarcity of treatment options. Traditional lipid-lowering drugs — fibrates, statins, and omega-3 fatty acids — often have limited efficacy in sHTG and rarely lower triglycerides below the safety threshold. It was not until June 2026 that Ionis Pharmaceuticals’ olezarsen became the first therapy specifically approved for lowering triglycerides and reducing acute pancreatitis risk in sHTG. Against this backdrop of unmet medical need, the plozasiran Phase III data are particularly noteworthy.

Robust Data

Plozasiran is a GalNAc-conjugated siRNA therapy designed to degrade APOC3 mRNA in the liver. In human lipid metabolism, APOC3 is synthesized primarily by hepatocytes and acts in two ways: it inhibits lipoprotein lipase (LPL) activity, hindering TG hydrolysis, and it impairs hepatic receptor-mediated uptake and clearance of TG-rich lipoprotein remnants.

Plozasiran specifically binds and degrades APOC3 mRNA, silencing APOC3 at the post-transcriptional level and substantially reducing hepatic APOC3 protein synthesis. As APOC3 levels fall, lipoprotein lipase activity is restored, ultimately driving substantial reductions in blood triglycerides and rebalancing lipid metabolism.

The newly announced SHASTA-3 and SHASTA-4 are two global, double-blind, placebo-controlled Phase III clinical trials that together enrolled approximately 750 sHTG patients, evaluating plozasiran’s efficacy and safety across a broad sHTG population. Participants received 25 mg plozasiran subcutaneously every 3 months for a total of four doses. The primary endpoint was the percent change from baseline in fasting serum triglycerides at month 12 (versus placebo).

Results showed that, at month 12, the median TG reduction was 79% in SHASTA-3 and 81% in SHASTA-4, compared with approximately 27% in the placebo arms. Both trials met their primary triglyceride endpoint.

If the magnitude of triglyceride reduction was striking, the significant decrease in acute pancreatitis events represents the major breakthrough of these trials.

In a pre-specified pooled analysis, the rate of acute pancreatitis events (proportion of patients experiencing at least one AP event) was significantly lower in the plozasiran group than in placebo (p<0.0221), and total AP events were also significantly reduced (p<0.0077). Across the overall sHTG population (TG>500 mg/dL, with or without prior AP), plozasiran reduced cumulative AP events by 78%.

The most striking finding came from the high-risk subgroup: among patients with TG>880 mg/dL and a history of prior AP — the highest-risk subgroup — plozasiran achieved a 100% reduction in AP events, with no events in the treatment arm versus several in the placebo arm.

For sHTG patients, acute pancreatitis is the most feared complication: recurrent episodes, repeated hospitalizations, and life-threatening consequences. The ability to substantially reduce AP risk in the highest-risk population suggests that, in the most vulnerable patients, plozasiran may potentially eliminate the threat of acute pancreatitis.

Because high-risk subgroups are typically where AP events cluster, a 100% risk reduction is likely to attract significant attention from regulators such as the FDA and EMA, as well as payers. In the absence of other effective prevention, this result may provide the strongest case for including plozasiran in clinical practice guidelines.

In terms of safety, the overall treatment-emergent adverse event (TEAE) profile and drug-related TEAEs were consistent with previously established safety data, with no new safety signals identified.

Two Powerhouses Compete

In the lipid-lowering arena, particularly in the competition around the APOC3 target, plozasiran’s most direct competitor is Ionis Pharmaceuticals’ antisense oligonucleotide (ASO) Tryngolza (olezarsen).

In terms of approval timing, Ionis moved first, securing two indications: in December 2024, Tryngolza received FDA approval for familial chylomicronemia syndrome (FCS) in adults, becoming the world’s first approved FCS therapy; in June 2026, Tryngolza received FDA approval for the sHTG indication, capturing first-mover advantage.

Arrowhead followed close behind: plozasiran’s FCS indication was approved in November 2025. Following the SHASTA-3/4 readout, the company plans to submit a supplemental New Drug Application (sNDA) for the sHTG indication by the end of 2026.

For the two Phase III CORE and CORE2 trials of olezarsen in sHTG, placebo-adjusted mean reductions in fasting triglycerides at 6 months ranged from 49% to 72% across dose groups. In contrast, plozasiran’s Phase III trials showed median TG reductions of 79% to 81% at 12 months. Although no head-to-head trial has been conducted, analysts have labeled plozasiran a “potential best-in-class” candidate. While Tryngolza enjoys a first-mover time advantage, Arrowhead’s strong plozasiran data may challenge Ionis’s market position going forward.

From a convenience standpoint, plozasiran requires only one subcutaneous injection every 3 months, whereas Tryngolza requires monthly injections. For chronic disease patients requiring long-term treatment, less frequent dosing means higher adherence and better quality of life — a meaningful commercial advantage for plozasiran.

Of course, first-movers have their moat. Building physician prescribing habits, insurance coverage, and brand recognition all take time, and Arrowhead will need to invest significant resources in commercialization.

It is worth noting that the two companies are engaged in a patent dispute centered on APOC3/FCS method patents. The dispute concerns whether Arrowhead’s plozasiran infringes Ionis’s patents covering olezarsen. In September 2025, Arrowhead filed a declaratory judgment action in Delaware, asserting invalidity and non-infringement; Ionis subsequently counter-sued for infringement in the Central District of California. As of July 2026, no settlement has been announced and no judgment has been issued; the litigation remains ongoing.

Market Opportunity

According to forecasts by multiple institutions, the global sHTG treatment market size is expected to reach approximately USD 876 million in 2025 and USD 2.267 billion by 2032, representing a compound annual growth rate (CAGR) of approximately 14.8%. Another institution projects the market size to be around USD 3.2 billion in 2024, potentially growing to USD 5.6 billion by 2033. In 2025, Olezarsen’s global sales are projected to be approximately USD 108 million. As their indications expand from rare diseases to common chronic conditions, both drugs are poised to capture significant market share in this rapidly expanding market.

FCS affects only around 3,000 patients in the U.S. and qualifies as an ultra-rare disease, while sHTG affects approximately 3 million Americans. Ionis’s CEO has clearly stated that the company is focusing on the high-risk TG>880 mg/dL population (approximately 500,000 individuals), while Arrowhead’s SHASTA-3/4 trials enrolled a broader TG≥500 mg/dL population (with or without prior AP), covering a larger patient base.

Arrowhead plans to file an sNDA for the sHTG indication with the FDA by the end of 2026, drawing on data from SHASTA-3, SHASTA-4, and the MUIR-3 trial in moderate hypertriglyceridemia (TG 150–500 mg/dL). In addition, the SHASTA-5 trial — specifically designed to evaluate plozasiran’s effect on pancreatitis prevention in high-AP-risk sHTG patients — is ongoing; positive results would provide more direct evidence of plozasiran’s pancreatitis-protective effect.

With substantial clinical benefit and quarterly dosing convenience, plozasiran is positioned to capture meaningful share in the rapidly growing sHTG market, with meaningful commercial potential.

Conclusion

With triglyceride reductions of 79% and 81%, complete elimination of AP events in the highest-risk subgroup, and a consistently favorable long-term safety profile, plozasiran has established a strong competitive position in severe hypertriglyceridemia. As Arrowhead advances its plan to file the sNDA by year-end, the contest to reshape the global lipid-lowering landscape around the APOC3 target has formally begun. Between the two powerhouses, who will prevail? The answer is gradually emerging from the interplay of clinical data and commercial strategy.

0
0
Loading